Why I Applied For The Chase Sapphire Preferred Even Though I Already Had The Chase Sapphire Reserve
Like many people who fuel their travel dreams with points and miles, I'm always on the hunt for big rewards opportunities. So the latest 100,000-point welcome offer for the Chase Sapphire Preferred® Card immediately activated the pleasure-seeking part of my brain. I can't even tell you the daydreams I started having about where my family could go with 100K Chase Ultimate Rewards® points. (It probably rhymes with Shmeroo, has ancient ruins and llamas and has been on my bucket list for quite some time).
Of course, big bonuses usually come with big spending requirements—and the Chase Sapphire Preferred® Card is no exception, with a welcome offer of 100,000 bonus points after spending $5,000 on purchases in the first three months from account opening. But fortune favors the bold, and as it turns out, my family had a sizable summer bill coming up and we had the cash ready to pay it off immediately. I also confirmed on my tracking sheet (what did you expect? I'm a credit card reporter!) that I was under 5/24—meaning I've been approved for less than five cards in the past 24 months—and thus eligible to apply for a new Chase card. So the timing was right.
However, there was one big barrier between me and llama nirvana. I already owned a Chase Sapphire Reserve®, which made me ineligible for the bonus—at least without a little maneuvering.
Earn 100,000 bonus points after you spend $5,000 on purchases in the first 3 months from account ... More opening.
Chase Sapphire Preferred® Card - See Rates & Fees
Chase Sapphire cards only allow you to earn a welcome bonus on a card if you don't currently own a Sapphire card and if you haven't earned the welcome bonus on a Sapphire card within the previous 48 months. I applied for and received my Chase Sapphire Reserve card way back in February 2017. The card launched in 2016 with a then-groundbreaking 100,000-point welcome offer.
I was fairly new to points and miles at the time, and this was my first premium credit card. I had a lot of fun using that bonus (rewards history fans may fondly recall the Marriott/United packages that were a steal back then), and it got me hooked on the thrill of taking trips I would have otherwise not been able to do. Points and miles have made impossible travel dreams for me and my family possible by greatly reducing our out-of-pocket costs.
I know, I'm getting misty-eyed too, and you haven't even seen how cute my kids are on our adventures. The crucial point here is that I got my Chase Sapphire Reserve in 2017, so I was well past the 48-month threshold to be eligible for a bonus on a Sapphire card. That put the Sapphire Preferred's bonus one step closer within reach.
To completely qualify for the Sapphire Preferred, I also had to not be a Sapphire cardholder at the time of my application. Yes, that means it was time to say farewell to my trusty Reserve.
I can't lie, I had some feelings about it. It was a gateway card to a whole new world of opportunity for me. But in this case, change was necessary. I called Chase and asked to downgrade my Reserve to the no-annual-fee Chase Freedom Unlimited®. Boom! I was no longer a Sapphire cardholder (for the moment).
Downgrading kept my account number the same, but the card's rewards rates and other details were now those of the Freedom Unlimited. There was no hard credit pull and the new card is on its way in the mail, but in the meantime, I could just keep using the metal card that was formerly known as my Reserve card.
I waited a few days to make sure everything was switched over, and then I applied online for my new Chase Sapphire Preferred. And I'm pleased to report that I was approved! I've uploaded it to my Apple Wallet, and now I'm just waiting for the physical card in the mail.
It's important to know that while you can downgrade a card at any time by swapping it for an eligible one by the same issuer at a lower fee, you cannot upgrade to a card with a higher annual fee for a minimum of a year after getting the original card. Federal legislation known as the CARD Act of 2007 includes a provision that prohibits issuers from raising your annual fee on a card within the first year after opening your account.
This means if you really want the Sapphire Reserve but are thinking about going for the Sapphire Preferred for the bonus and then later upgrading, you'll have to wait a full year to do so.
If you already own a Sapphire card, but you've had it for over 48 months, you might be able to put yourself in an eligible position to apply for the current 100,000-point welcome offer on the Chase Sapphire Preferred. There are a few boxes to check off, but if you're under 5/24, this is a bonus worth going for.
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not offer financial advice, advisory or brokerage services, nor do we recommend or advise individuals or to buy or sell particular stocks or securities. Performance information may have changed since the time of publication. Past performance is not indicative of future results.
Forbes Advisor adheres to strict editorial integrity standards. To the best of our knowledge, all content is accurate as of the date posted, though offers contained herein may no longer be available. The opinions expressed are the author's alone and have not been provided, approved, or otherwise endorsed by our partners.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
StealthCores Joins Microchip Partner Program to Deliver Advanced Security for PolarFire FPGA and SoC Platforms
Partnership delivers optimized encryption solutions for mission-critical applications Gainesville, FL, June 04, 2025 (GLOBE NEWSWIRE) -- StealthCores, a provider of advanced encryption IP for secure systems, has joined the Microchip Partner Program to deliver cutting-edge protection for PolarFire® FPGA and PolarFire SoC platforms. The partnership enables customers to leverage StealthCores' specialized encryption technologies, StealthAES and StealthMem, which are now fully optimized for the PolarFire architecture. These solutions complement Microchip's built-in security features, providing additional performance and capabilities while maintaining the highest levels of protection against side-channel attacks. "Our close collaboration with Microchip allows us to deliver security solutions that are precisely tailored to the unique capabilities of the PolarFire platform," said Stuart Audley, President of StealthCores. "As security threats continue to evolve, this partnership ensures that customers have access to the most advanced encryption technologies available for their mission-critical applications." StealthAES implements high-performance AES-GCM encryption secured with advanced countermeasures for enhanced protection on PolarFire platforms, while StealthMem delivers comprehensive memory encryption across RAM, flash, and PCIe® NVMe® interfaces. Together, these solutions address the growing need for comprehensive data protection in edge computing, communications infrastructure, defense systems, and industrial applications. The partnership also enables StealthCores to offer PolarFire implementation services, helping customers integrate advanced security features using the embedded Athena TeraFire cryptoprocessor and PCIe subsystem. This approach enables efficient integration of even the most complex security requirements. "As security becomes a non-negotiable in defense, industrial, and communications sectors, our partnership with StealthCores ensures developers have direct access to field-tested encryption tools that meet real-world requirements," said Shakeel Peera Vice President of Marketing and Strategy for Microchip's FPGA business unit. "By leveraging StealthAES and StealthMem technologies in Microchip's PolarFire FPGA architecture, we're pushing the boundaries of what's possible in FPGA security." StealthCores' solutions are now available for PolarFire FPGA and SoC platforms through the Microchip Partner Program. About StealthCores StealthCores develops advanced security IP for FPGAs and ASICs, delivering practical, high-performance cryptographic solutions with built-in countermeasures against side-channel attacks. Backed by decades of industry experience and purpose-built IP, StealthCores enables customers to secure critical systems with confidence. Learn more at or contact us at info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
PVH (NYSE:PVH) Surprises With Q1 Sales But Stock Drops
Fashion conglomerate PVH (NYSE:PVH) reported revenue ahead of Wall Street's expectations in Q1 CY2025, with sales up 1.6% year on year to $1.98 billion. Its non-GAAP profit of $2.30 per share was 2.2% above analysts' consensus estimates. Is now the time to buy PVH? Find out in our full research report. Revenue: $1.98 billion vs analyst estimates of $1.93 billion (1.6% year-on-year growth, 2.6% beat) Adjusted EPS: $2.30 vs analyst estimates of $2.25 (2.2% beat) Adjusted EBITDA: -$264.5 million vs analyst estimates of $233.8 million (-13.3% margin, significant miss) Management lowered its full-year Adjusted EPS guidance to $10.88 at the midpoint, a 13.5% decrease Operating Margin: -16.7%, down from 10.5% in the same quarter last year Constant Currency Revenue rose 2% year on year (-8.7% in the same quarter last year) Market Capitalization: $4.34 billion Stefan Larsson, Chief Executive Officer, commented, 'In Q1, we continued to tap into the global consumer love for Calvin Klein and TOMMY HILFIGER, delivering revenue growth versus last year and ahead of guidance. Calvin Klein saw one of its most impactful product launches in years with the Icon Cotton Stretch franchise, amplified by the viral Bad Bunny campaign. TOMMY HILFIGER tapped into its lifestyle DNA with rich product storytelling around seasonal newness of Tommy classics to drive growth and built momentum for the brand's collaboration with the biggest movie launch of the summer: F1® The Movie.' Founded in 1881 by a husband and wife duo, PVH (NYSE:PVH) is a global fashion conglomerate with iconic brands like Calvin Klein and Tommy Hilfiger. Examining a company's long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Unfortunately, PVH struggled to consistently increase demand as its $8.68 billion of sales for the trailing 12 months was close to its revenue five years ago. This wasn't a great result and is a sign of poor business quality. We at StockStory place the most emphasis on long-term growth, but within consumer discretionary, a stretched historical view may miss a company riding a successful new product or trend. PVH's recent performance shows its demand remained suppressed as its revenue has declined by 2.1% annually over the last two years. PVH also reports sales performance excluding currency movements, which are outside the company's control and not indicative of demand. Over the last two years, its constant currency sales averaged 2.3% year-on-year declines. Because this number aligns with its normal revenue growth, we can see that PVH has properly hedged its foreign currency exposure. This quarter, PVH reported modest year-on-year revenue growth of 1.6% but beat Wall Street's estimates by 2.6%. Looking ahead, sell-side analysts expect revenue to remain flat over the next 12 months. Although this projection suggests its newer products and services will spur better top-line performance, it is still below average for the sector. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It's also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes. PVH's operating margin has shrunk over the last 12 months and averaged 6.6% over the last two years. The company's profitability was mediocre for a consumer discretionary business and shows it couldn't pass its higher operating expenses onto its customers. In Q1, PVH generated an operating margin profit margin of negative 16.7%, down 27.3 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue. We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. PVH's EPS grew at a spectacular 23.4% compounded annual growth rate over the last five years, higher than its flat revenue. However, this alone doesn't tell us much about its business quality because its operating margin didn't expand. In Q1, PVH reported EPS at $2.30, down from $2.45 in the same quarter last year. Despite falling year on year, this print beat analysts' estimates by 2.2%. Over the next 12 months, Wall Street expects PVH's full-year EPS of $11.61 to grow 13.8%. We enjoyed seeing PVH beat analysts' constant currency revenue and EPS expectations this quarter. On the other hand, its EBITDA missed and it lowered its full-year EPS guidance. Overall, this was a softer quarter. The stock traded down 5.3% to $76.50 immediately after reporting. PVH underperformed this quarter, but does that create an opportunity to invest right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Global AI in Remote Patient Monitoring Market to Cross USD 13 Billion by 2032
The AI in remote patient monitoring market is witnessing strong growth, driven by the increasing prevalence of chronic illnesses like cancer, cardiovascular conditions, and lifestyle-related disorders. This momentum is further boosted by a rise in product innovation, growing global investments in digital health infrastructure, and a heightened focus on proactive, data-centric healthcare approaches. These trends are anticipated to significantly accelerate the expansion of the AI-enabled RPM market throughout the forecast period of 2025 to 2032. New York, USA, June 04, 2025 (GLOBE NEWSWIRE) -- Global AI in Remote Patient Monitoring Market to Cross USD 13 Billion by 2032 | DelveInsight The AI in remote patient monitoring market is witnessing strong growth, driven by the increasing prevalence of chronic illnesses like cancer, cardiovascular conditions, and lifestyle-related disorders. This momentum is further boosted by a rise in product innovation, growing global investments in digital health infrastructure, and a heightened focus on proactive, data-centric healthcare approaches. These trends are anticipated to significantly accelerate the expansion of the AI-enabled RPM market throughout the forecast period of 2025 to 2032. DelveInsight's AI in Remote Patient Monitoring Market Insights report provides the current and forecast market analysis, individual leading AI in remote patient monitoring companies' market shares, challenges, AI in remote patient monitoring market drivers, barriers, trends, and key market AI in remote patient monitoring companies in the market. Key Takeaways from the AI in Remote Patient Monitoring Market Report As per DelveInsight estimates, North America is anticipated to dominate the global AI in remote patient monitoring market during the forecast period. In the product type segment of the AI in remote patient monitoring market, the devices category held the largest revenue share in 2024. Notable AI in remote patient monitoring companies such as Medtronic, iRhythm Inc., Koninklijke Philips N.V., Siemens Healthineers, GE HealthCare, Apple Inc., AliveCor Inc., Biofourmis, Optum, Inc., Headspace Health, Withings, NeuroRPM Inc., Caretaker Medical, Implicity, Stryker, Biobeat, and several others are currently operating in the AI in remote patient monitoring market. In September 2024, iRhythm Technologies announced the Japanese regulatory approval of the zio® ECG monitoring system, the first product to deliver arrhythmia monitoring service utilizing artificial intelligence. In April 2024, Royal Philips, a global leader in health technology, announced a strategic partnership to integrate smartQare's advanced solution, viQtor, with Philips' world-leading clinical patient monitoring platforms. This collaboration aims to enable the next generation of continuous patient monitoring both in and out of the hospital, starting in Europe. To read more about the latest highlights related to the AI in remote patient monitoring market, get a snapshot of the key highlights entailed in the Global AI in Remote Patient Monitoring Market Report AI in Remote Patient Monitoring Overview Artificial intelligence (AI) is revolutionizing remote patient monitoring (RPM) by enabling real-time, continuous health surveillance outside of traditional clinical settings. Through wearable devices and connected sensors, AI algorithms can analyze vital signs, detect anomalies, and predict potential health deterioration before symptoms become critical. This proactive approach allows for early interventions, reduces hospital readmissions, and improves chronic disease management, particularly for conditions like heart failure, diabetes, and COPD. By automating data analysis and triage, AI also significantly reduces the burden on healthcare professionals, allowing them to focus on patients who need urgent attention. Furthermore, AI-driven RPM fosters personalized care by learning from individual patient data over time. Machine learning models can adapt to each patient's unique health patterns, improving the accuracy of predictions and enabling tailored treatment plans. Natural language processing (NLP) tools can also interpret patient-reported symptoms via apps or voice interfaces, enriching the clinical picture. As AI technologies evolve, their integration into RPM systems is expected to enhance accessibility, especially in rural or underserved areas, bridging gaps in healthcare delivery while maintaining cost-efficiency and high-quality in Remote Patient Monitoring Market Insights North America is projected to lead the AI in remote patient monitoring market from 2025 to 2032. This dominance is largely driven by factors such as the growing prevalence of chronic diseases like cancer, a robust healthcare infrastructure, widespread adoption of digital health technologies, and supportive government initiatives. The region also benefits from significant investments in digital health and the extensive use of wearable and connected medical devices. The rising incidence of cancer in the U.S. and Canada is fueling the demand for continuous, home-based care solutions. This trend is accelerating the adoption of AI-driven remote patient monitoring, which enhances treatment management, symptom tracking, and patient outcomes outside traditional healthcare settings. Additionally, the increasing rates of cardiovascular diseases and related risk factors are heightening the need for ongoing and efficient monitoring solutions. AI-powered remote monitoring enables early detection, real-time intervention, and personalized care for heart patients, particularly in aging populations, thereby reducing complications and improving outcomes. Together, these factors create a favorable landscape for market expansion, solidifying North America's position as the leading region in the AI-based remote patient monitoring market throughout the forecast period. To know more about why North America is leading the market growth in the AI in remote patient monitoring market, get a snapshot of the AI in Remote Patient Monitoring Market Outlook AI in Remote Patient Monitoring Market Dynamics The AI in remote patient monitoring market is undergoing rapid transformation, driven by the convergence of advanced technologies, shifting healthcare models, and an increasing emphasis on personalized care. Artificial Intelligence is enhancing RPM systems by enabling real-time data analysis, predictive analytics, and automation, thereby helping providers manage chronic diseases, post-operative care, and elderly patients more effectively. AI algorithms can analyze vast volumes of patient data from wearable devices and home-based monitoring systems, identifying anomalies and alerting care teams before a crisis occurs. This proactive capability is fueling demand, particularly in value-based care models where preventing hospital readmissions is key. One of the primary drivers of this market is the global increase in chronic diseases and aging populations, which has led to an urgent need for continuous and cost-effective patient monitoring. AI-based RPM solutions not only reduce the burden on healthcare systems but also empower patients to manage their conditions better. Furthermore, the COVID-19 pandemic accelerated adoption, normalizing virtual care and remote diagnostics. This shift has continued post-pandemic, with healthcare providers and payers increasingly investing in AI-driven tools to support hybrid care models and decentralize service delivery. However, the market is not without its challenges. Data privacy, regulatory hurdles, and interoperability issues are key barriers to widespread adoption. The effectiveness of AI algorithms depends heavily on access to high-quality, diverse datasets, and data silos across healthcare institutions can limit this. Additionally, regulatory frameworks are still evolving to keep pace with AI's rapid advancement, and there's ongoing scrutiny about algorithmic bias and accountability. Addressing these challenges is crucial for building trust among clinicians and patients alike. On the competitive front, the market is witnessing intense innovation and strategic partnerships among tech firms, medtech companies, and healthcare providers. Startups are emerging with specialized AI capabilities in areas like arrhythmia detection, diabetic monitoring, and mental health assessment, while major players are integrating AI into their existing RPM platforms. Cloud infrastructure providers and AI-as-a-service vendors are also playing a key role in scaling solutions across geographies. Looking ahead, the AI in RPM market is expected to experience sustained growth, driven by advances in sensor technology, 5G connectivity, and federated learning models that allow privacy-preserving data sharing. As AI becomes more explainable and transparent, its integration into clinical workflows will deepen, making remote monitoring an integral part of mainstream healthcare delivery. Get a sneak peek at the AI in remote patient monitoring market dynamics @ AI in Remote Patient Monitoring Market Dynamic Analysis Report Metrics Details Coverage Global Study Period 2022–2032 AI in Remote Patient Monitoring Market CAGR ~27% AI in Remote Patient Monitoring Market Size by 2032 USD 13.1 Billion Key AI in Remote Patient Monitoring Companies Medtronic, iRhythm Inc., Koninklijke Philips N.V., Siemens Healthineers, GE HealthCare, Apple Inc., AliveCor Inc., Biofourmis, Optum, Inc., Headspace Health, Withings, NeuroRPM Inc., Caretaker Medical, Implicity, Stryker, Biobeat, among others AI in Remote Patient Monitoring Market Assessment AI in Remote Patient Monitoring Market Segmentation AI in Remote Patient Monitoring Market Segmentation By Product Type: Devices, Software, and Services AI in Remote Patient Monitoring Market Segmentation By Application: Cancer, Cardiovascular Disorder, Lifestyle Disorders, and Others AI in Remote Patient Monitoring Market Segmentation By End User: Hospitals and Clinics, Diagnostic Centers, and Homecare Setting AI in Remote Patient Monitoring Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the AI in remote patient monitoring market are set to emerge as the trendsetter explore @ AI in Remote Patient Monitoring Companies Table of Contents 1 AI in Remote Patient Monitoring Market Report Introduction 2 AI in Remote Patient Monitoring Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 AI in Remote Patient Monitoring Market Key Factors Analysis 6 AI in Remote Patient Monitoring Market Porter's Five Forces Analysis 7 AI in Remote Patient Monitoring Market Layout 8 AI in Remote Patient Monitoring Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the AI in remote patient monitoring market by 2032? Click to get a snapshot of the AI in Remote Patient Monitoring Market Trends Related Reports Patient Monitoring Devices Market Patient Monitoring Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key patient monitoring devices companies, including Medtronic plc, GE Healthcare, Philips Healthcare, Abbott Laboratories, Siemens Healthineers, Nihon Kohden Corporation, Masimo Corporation, Omron Healthcare Co., Ltd., Smiths Medical, Hillrom, Welch Allyn, Inc., Natus Medical Incorporated, Mindray Medical International Limited, Nonin Medical, Inc., Spacelabs Healthcare, among others. Artificial Intelligence in Drug Commercialization Market Artificial Intelligence in Drug Commercialization Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in drug commercialization companies, including EVERSANA, Lyfegen, Syneos Health, McKinsey & Company, ICON plc., Clarivate., Thermo Fisher Scientific Inc., Viseven, ZS Associates, Cloud Pharmaceuticals Inc., among others. Artificial Intelligence in Precision Medicine Market Artificial Intelligence in Precision Medicine Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in precision medicine companies, including TEMPUS, GE HealthCare, Envisionit Deep AI (Pty) Ltd., Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., among others. Artificial Intelligence In Drug Discovery Market Artificial Intelligence In Drug Discovery Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in drug discovery companies, including IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Atomwise Inc, Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), Insilico Medicine, BenevolentAI, Exscientia, Cyclia, Valo Health, Owkin Inc, Verge Genomics, BioSymetrics, among others. Artificial Intelligence in Medical Imaging Market Artificial Intelligence in Medical Imaging Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in medical imaging companies, including Microsoft, Siemens Healthineers, GE Healthcare, NVIDIA Corporation, Philips Healthcare, Arterys, Butterfly Network, Enlitic, HeartFlow, Digital Diagnostics, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us Shruti Thakur info@ +14699457679
